Saturday 17 October 2026
Export CSLT’s income statement to Excel — free account
Castlight Health, inc.
CSLT Healthcare Health Information Services
Operating cash flow growth for ten consecutive years.
2.05
0.00
0.00%
Follow CSLT
| Older periods | Dec '20 | Mar '21 | Jun '21 | Sep '21 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.34 | 1.66 | 2.93 | 1.77 | |
P/FCF ratio |
0.00 | 17.10 | 24.07 | 12.56 | |
P/Operating CF |
66.55 | 31.25 | 90.41 | 43.33 | |
P/B ratio |
1.59 | 1.90 | 3.34 | 1.99 | |
Price to Tangible BV |
2.65 | 3.11 | 5.36 | 3.13 | |
EV/Sales |
1.11 | 1.35 | 2.58 | 1.38 | |
EV/EBITDA |
30.29 | 26.56 | 42.41 | 28.92 | |
EV/Operating CF |
(29.17) | 11.79 | 20.58 | 9.34 | |
EV/FCF |
(17.75) | 13.94 | 21.20 | 9.74 | |
Quick Ratio |
2.36 | 2.31 | 2.57 | 2.73 | |
Current Ratio |
2.47 | 2.50 | 2.84 | 2.94 | |
Net Debt/EBITDA |
(13.55) | (124.45) | (62.84) | (38.04) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.72 | 0.82 | 0.85 | 0.86 | |
Operating CF/Net income |
(2.47) | (2.53) | (1.94) | (2.87) | |
Capex/Depreciation |
(0.03) | (0.06) | (0.01) | (0.13) | |
Research and Development Expense of Revenue |
30.79% | 34.55% | 34.59% | 33.45% | |
Selling, General and Administrative Expense of Revenue |
38.07% | 37.88% | 38.13% | 38.17% | |
Intangible Assets out of Total Assets |
0.30 | 0.29 | 0.29 | 0.28 | |
Share Based Compensation of Revenue |
7.78% | 8.86% | 8.90% | 9.20% | |
Graham Net Nets |
0.21 | 0.20 | 0.13 | 0.23 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.31%) | (3.97%) | (1.90%) | (3.82%) | |
Free Cash Flow Yield |
(4.64%) | 5.85% | 4.16% | 7.96% | |
Revenue per Share |
0.24 | 0.22 | 0.22 | 0.22 | |
Operating CF per Share |
0.02 | 0.05 | 0.03 | 0.04 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | 0.05 | 0.03 | 0.03 | |
Cash per Share |
0.33 | 0.36 | 0.38 | 0.41 | |
Shareholders Equity per Share |
0.82 | 0.79 | 0.79 | 0.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 0.79 | 0.79 | 0.79 | |
Free Cash Flow |
2.81 | 7.36 | 4.59 | 5.38 | |
Working Capital |
50.47 | 53.04 | 59.06 | 63.46 | |
Capital Expenditures |
(0.15) | (0.21) | (0.03) | (0.46) | |
Net Current Asset Value |
41.88 | 46.53 | 54.30 | 58.84 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.57 | 31.55 | 27.46 | 26.88 | |
Average Payables |
12.37 | 8.84 | 6.17 | 4.62 | |
Average Assets |
204.78 | 173.41 | 167.19 | 166.16 | |
Average Common Equity |
148.37 | 122.23 | 122.21 | 124.57 |
Columns are period end dates